SCHEMBL3548500

SCHEMBL3548500

O=C(c1c[nH]nc1-c1cc(Cl)c(O)cc1O)N1CCN(c2ccccc2)CC1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 2/20 0.67
▸ ALDH1A1 P00352 7/20 0.50
▸ KMT2A Q03164 4/20 0.50
▸ TSHR P16473 3/20 0.50
▸ MEN1 O00255 3/20 0.50
▸ USP2 O75604 2/20 0.50
▸ GFER P55789 1/20 0.46
▸ LMNA P02545 4/20 0.45
▸ HTT P42858 2/20 0.45
▸ TACR3 P29371 1/20 0.45
▸ MAPT P10636 2/20 0.45
▸ TP53 P04637 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ MAPK1 P28482 1/20 0.44
▸ HSP90AB1 P08238 1/20 0.43
▸ PDK1 Q15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3549227 0.85 HSP90AA1 (0.61) HSP90AA1TSHRHTTMAPTHSP90AB1
SCHEMBL3545882 0.85 HSP90AA1 (0.61) HSP90AA1KMT2ATSHRLMNATP53
SCHEMBL3087949 0.77 HSP90AA1 (0.48) HSP90AA1ALDH1A1TP53HSP90AB1
SCHEMBL3093609 0.74 HSP90AA1 (0.61) HSP90AA1KMT2AMEN1USP2LMNA
SCHEMBL15103620 0.73 HSP90AA1 (0.49) HSP90AA1HSP90AB1
SCHEMBL13151325 0.73 HSP90AA1 (0.44) HSP90AA1HSP90AB1
SCHEMBL13627501 0.72 ALDH1A1 (0.46) HSP90AA1ALDH1A1KMT2ATSHRMEN1
SCHEMBL13151404 0.71 HSP90AA1 (0.64) HSP90AA1HSP90AB1
SCHEMBL4481238 0.71 SMARCA2 (0.48) HSP90AA1ALDH1A1KMT2AMEN1LMNA
SCHEMBL13627517 0.70 HSP90AA1 (0.53) HSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 AMGEN INC. 2008-01-24 — — US claimed
US-7803831-B2 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2010-09-28 — — US disclosed
US-7803831-B2 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2010-09-28 — — US disclosed
US-7666888-B2 Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 AMGEN INC. (US) 2010-02-23 — — US disclosed
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 AMGEN INC. 2008-01-24 — — US disclosed
US-20070112192-A1 3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-05-17 — — US disclosed
US-20070112192-A1 3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 HSD17B1, HSD11B1, HSD17B11 HSP90AA1 1231/4885ALDH1A1 86/4885KMT2A 2389/4885
US-20070112192-A1 3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer HSP90AB1, HSP90AA1, HSP90AB2P HSP90AA1 2/4885ALDH1A1 197/4885KMT2A 4021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback